Source:http://linkedlifedata.com/resource/pubmed/id/17475871
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2007-5-3
|
pubmed:abstractText |
Most C57BL/6 mice infected i.p. with Plasmodium berghei ANKA (PbA) die between 7 and 14 days with neurologic signs, and the remainder die later (>15 days) with severe anemia. Daily i.p. injections of a recombinant human IFN-alpha (active on mouse cells) prevented death by cerebral malaria (87% deaths in the control mice vs 6% in IFN-alpha-treated mice). The mechanisms of this IFN-alpha protective effect were multiple. IFN-alpha-treated, PbA-infected mice showed 1) a marked decrease in the number of PbA parasites in the blood mediated by IFN-gamma, 2) less sequestered parasites in cerebral vessels, 3) reduced up-regulation of ICAM-1 expression in brain endothelial cells, 4) milder rise of blood levels of TNF, 5) increased levels of IFN-gamma in the blood resulting from an increased production by splenic CD8+ T cells, and 6) fewer leukocytes (especially CD8+ T cells) sequestered in cerebral vessels. On the other hand, IFN-alpha treatment did not affect the marked anemia observed in PbA-infected mice. Survival time in IFN-alpha-treated mice was further increased by performing three blood transfusions over consecutive days.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0022-1767
|
pubmed:author |
pubmed-author:BelnoueElodieE,
pubmed-author:DescheminJean-ChristopheJC,
pubmed-author:GrünerAnne CharlotteAC,
pubmed-author:GresserIonI,
pubmed-author:KayibandaMichèleM,
pubmed-author:MarussigMyriamM,
pubmed-author:MauduitMarjorieM,
pubmed-author:MazierDominiqueD,
pubmed-author:RéniaLaurentL,
pubmed-author:SnounouGeorgesG,
pubmed-author:VigárioAna MargaridaAM
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
178
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
6416-25
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:17475871-Anemia,
pubmed-meshheading:17475871-Animals,
pubmed-meshheading:17475871-Female,
pubmed-meshheading:17475871-Humans,
pubmed-meshheading:17475871-Injections, Intraperitoneal,
pubmed-meshheading:17475871-Interferon Type I,
pubmed-meshheading:17475871-Malaria, Cerebral,
pubmed-meshheading:17475871-Mice,
pubmed-meshheading:17475871-Mice, Inbred C57BL,
pubmed-meshheading:17475871-Parasitemia,
pubmed-meshheading:17475871-Plasmodium berghei,
pubmed-meshheading:17475871-Recombinant Proteins
|
pubmed:year |
2007
|
pubmed:articleTitle |
Recombinant human IFN-alpha inhibits cerebral malaria and reduces parasite burden in mice.
|
pubmed:affiliation |
Institut Cochin, Département d'Immunologie, Paris, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|